Montvale, NJNCT07768436Now EnrollingIRB Ready

Adenocarcinoma of the Breast Clinical Trial in Montvale, NJ

Access cutting-edge adenocarcinoma of the breast treatment through this phase 2 clinical trial at a research site in Montvale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Montvale location

Preparing your pre-screening questions…

Expert Care in Montvale

Access adenocarcinoma of the breast specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related adenocarcinoma of the breast treatment provided free

Apply for This Montvale Location

Check if you qualify for this adenocarcinoma of the breast clinical trial in Montvale, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Montvale

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Montvale site if eligible
  4. 4Begin participation

About This Adenocarcinoma of the Breast Study in Montvale

The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients must have histologically confirmed adenocarcinoma of the breast confirmed at MSK. The patient must have had diagnostic biopsy or completion of primary surgical management, within 3 months of enrollment. Results of HER-2/neu, estrogen receptor, and progesterone receptor are required for study entry.
Patients must be ≥ 70 years of age.
Patients must have ECOG performance status \>2 (Karnofsky score of ≥ 60%).
Patients may have received hormonal therapy for the purpose of chemoprevention.
Adjuvant/neoadjuvant chemotherapy decision to treat based on the discretion of investigator
Cohort 1 only: Patients have any histology except Her 2 Neu positive in the adjuvant or neoadjuvant setting
Cohort 2 only: Patients have triple negative (ER- (10%) PR-Her 2 Neu -) in the neoadjuvant setting
Cohort 2 only: Patients have received at least 1 dose of carboplatin/paclitaxel +/- pembrolizumab in the neoadjuvant setting Required Organ Function Adequate hematologic function defined as follows:
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
Platelets ≥ 100,000 cells/mm3 Adequate renal function defined as follows: ° Creatinine clearance (CrCL) of \>30 mL/min by the Cockcroft-Gault formula: CrCl (mL/min) = \[(\[140 - age(years)\] x weight (kg))/72 x creatinine (mg/dL)\] (x 0.85 for female patients) Adequate hepatic function defined as follows:
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
AST and ALT ≤3 x institutional ULN
Patients or their Legally Authorized Representative must give written, informed consent indicating their understanding and willingness to participate in the study.

Exclusion Criteria

Stage IV breast cancer
CARG score- high Frail 4 or more as assessed by CAIT
Her 2 Neu positive 3+/amplified breast cancer
No prior chemotherapy within 1 year of study enrollment
Cohort 2 only: patients may not receive pembrolizumab during dd CMF treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Montvale?

Yes, this clinical trial (NCT07768436) has an active research site in Montvale, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Adenocarcinoma of the Breast Treatment Options in Montvale, NJ

If you're searching for adenocarcinoma of the breast treatment options in Montvale, NJ, this clinical trial (NCT07768436) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Montvale research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced adenocarcinoma of the breast specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all adenocarcinoma of the breast clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Montvale, NJ

See all alzheimers disease clinical trials recruiting in Montvale — not just this study.

Browse Alzheimers Disease Trials in Montvale →

Ready to Join in Montvale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Montvale, NJ